Search Results

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.

• Authors : Gallien, S; Journot, V; Loriot, M‐A

Subjects: THERAPEUTIC use of protease inhibitors; DIDANOSINE (Drug); EMTRICITABINE

• Source: HIV Medicine. Sep2017, Vol. 18 Issue 8, p537-545. 9p.

Record details

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

• Authors : Rosenstock, Julio; Perkovic, Vlado; Johansen, Odd Erik

Subjects: CD26 antigen; CHEMICAL inhibitors; DRUG side effects

• Source: JAMA: Journal of the American Medical Association; 1/1/2019, Vol. 321 Issue 1, p69-79, 11p

Record details

Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.

• Authors : Rubio, R; Serrano, O; Carmena, J

Subjects: THERAPEUTIC use of protease inhibitors; ANALYSIS of variance; ANTIVIRAL agents

• Source: HIV Medicine. Oct2010, Vol. 11 Issue 9, p545-553. 9p. 1 Diagram, 2 Charts, 2 Graphs.

Record details

Evaluation of the Side Effects of Antiretroviral Treatment.

• Authors : BAŞGÖNÜL, Sedef; GENÇER, Serap; ÖZER, Serdar

Subjects: ANTIRETROVIRAL agents; DRUG side effects; THERAPEUTIC use of protease inhibitors

• Source: Mediterranean Journal of Infection, Microbes & Antimicrobials; 2018, p1-8, 8p

Record details

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.

• Authors : Matsumoto, Nobuyuki; Ikeda, Hiroki; Shigefuku, Ryuta

Subjects: HEMOGLOBINS; VIRAL nonstructural proteins; THERAPEUTIC use of protease inhibitors

• Source: PLoS ONE; 3/18/2016, Vol. 11 Issue 3, p1-7, 7p

Record details

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection.

• Authors : Poordad, Fred; Sievert, William; Mollison, Lindsay

Subjects: CHRONIC hepatitis C; COMBINATION drug therapy; THERAPEUTIC use of protease inhibitors

• Source: JAMA: Journal of the American Medical Association; 5/5/2015, Vol. 313 Issue 17, p1728-1735, 8p, 4 Charts, 1 Graph

Record details

Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort.

• Authors : Kirk, O.; Gerstoft, J.; Pedersen, C.

Subjects: *HIV-positive persons; *THERAPEUTIC use of protease inhibitors; *DRUG side effects

• Source: HIV Medicine. Jan2001, Vol. 2 Issue 1, p43. 9p.

Record details

100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1--Infected Individuals).

Subjects: HEPATITIS C treatment; THERAPEUTIC use of interferons; THERAPEUTIC use of protease inhibitors

• Source: Gastroenterology & Hepatology; Dec2017, Vol. 13 Issue 12, Special section p18-20, 3p

Record details

Emerging Treatment Options in the Management of Multiple Myeloma.

• Authors : Schlossman, Robert L.

Subjects: THERAPEUTIC use of protease inhibitors; THALIDOMIDE; COMBINATION drug therapy

• Source: Journal of Managed Care Medicine; 2013, Vol. 16 Issue 1, p25-29, 5p, 1 Chart, 3 Graphs

Record details

Updates in the Guidelines and Treatment of Hepatitis C.

• Authors : Winston, David H.

Subjects: HEPATITIS C diagnosis; THERAPEUTIC use of interferons; THERAPEUTIC use of protease inhibitors

• Source: Journal of Managed Care Medicine; 2012, Vol. 15 Issue 4, p16-21, 6p, 3 Diagrams, 1 Graph

Record details